Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- Registration Number
- NCT03098030
- Lead Sponsor
- United Therapeutics
- Brief Summary
This is a 2-part, multicenter, open-label, randomized study of dinutuximab and irinotecan versus irinotecan alone in subjects with relapsed or refractory small cell lung cancer (SCLC). Part 1 of the study involves intrasubject dose escalation to evaluate the safety and tolerability of dinutuximab in combination with irinotecan. Part 2 of the study is designed to determine whether dinutuximab plus irinotecan prolongs overall survival (OS) compared with irinotecan alone. Subjects in Part 2 will be randomized in a 2:2:1 fashion to 1 of 3 treatment groups: (A) irinotecan; (B) dinutuximab plus irinotecan; or (C) topotecan. Randomization will be stratified by duration of response to prior platinum therapy (relapse-free period \<3 months or ≥3 months).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 483
- Have histologically or cytologically confirmed SCLC (undifferentiated small-cell carcinoma arising in or consistent with lung cancer origin).
- Documented relapse or disease progression during or after first-line platinum-based therapy (subjects refractory to initial platinum-based therapy are eligible).
- Have no curative therapy available.
- Have a life expectancy of at least 12 weeks.
- Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Have adequate bone marrow and hepatic function.
- Have calculated creatinine clearance (CrCL) ≥30 mL/minute or serum creatinine ≤1.5 times below the upper limit of normal.
- Women of reproductive potential must not be pregnant or breastfeeding and have a negative urine or serum pregnancy test obtained within 7 days prior to the first dose of study treatment.
- Subjects must agree to consistently use 2 forms of highly effective contraception/birth control between signing of the informed consent and 60 days after the last study drug administration.
- Candidate for re-treatment with original platinum-based regimen as second-line therapy.
- Prior treatment with irinotecan, topotecan, or dinutuximab.
- Have active brain metastases. Subjects with brain metastases are allowed if they completed definitive brain therapy, are asymptomatic and radiologically stable, and if they are not currently receiving corticosteroids or radiation.
- Have mixed small cell and non-small cell histologic features.
- Have a previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta and Tis [carcinoma in situ]) or any previous cancer curatively treated <3 years ago.
- Have a history or current evidence of uncontrolled cardiovascular disease.
- Have not recovered from prior surgery, significant trauma, systemic anticancer therapy, radiation therapy or investigational therapy to Grade 1 or better toxicity prior to enrollment (Part 1) or randomization (Part 2).
- Have had organ allograft or hematopoietic transplantation.
- Known to be human immunodeficiency virus (HIV) positive.
- Have an active infection requiring treatment or one that is clinically serious in the Investigator's opinion.
- Have received a live vaccine within 6 months of enrollment (Part 1) or randomization (Part 2).
- Exposure to strong CYP3A4 and/or UGT1A1 inhibitors and strong CYP3A4 inducers within 14 days of enrollment (Part 1) or randomization (Part 2).
- Have any clinical condition that is considered unstable or might jeopardize the safety of the subject and/or influence the subject's compliance in the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Part 1: Dinutuximab + Irinotecan Dinutuximab Dinutuximab (10 mg/m\^2 IV) + Irinotecan (350 mg/m\^2 IV) on Day 1 of every 21 days (q21d). Dinutuximab dose will be escalated in 2 mg/m\^2 increments per cycle if maximal pain is \<Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m\^2 IV. Part 2: Dinutuximab + Irinotecan Dinutuximab Dinutuximab (16 mg/m\^2 IV) + Irinotecan (350 mg/m\^2 IV) on Day 1 of each q21d cycle. Dinutuximab dose will be escalated in 2 mg/m\^2 increments per cycle if maximal pain is \<Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m\^2 IV. Part 2: Irinotecan Irinotecan Irinotecan (350 mg/m\^2 IV) on Day 1 of each q21d cycle. Part 1: Dinutuximab + Irinotecan Irinotecan Dinutuximab (10 mg/m\^2 IV) + Irinotecan (350 mg/m\^2 IV) on Day 1 of every 21 days (q21d). Dinutuximab dose will be escalated in 2 mg/m\^2 increments per cycle if maximal pain is \<Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m\^2 IV. Part 2: Topotecan Topotecan Topotecan (1.5 mg/m\^2 IV) on Days 1 to 5 of each q21d cycle. Part 2: Dinutuximab + Irinotecan Irinotecan Dinutuximab (16 mg/m\^2 IV) + Irinotecan (350 mg/m\^2 IV) on Day 1 of each q21d cycle. Dinutuximab dose will be escalated in 2 mg/m\^2 increments per cycle if maximal pain is \<Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m\^2 IV.
- Primary Outcome Measures
Name Time Method Overall Survival (OS) Up to approximately 2.5 years OS will be derived as: (date of death - date of randomization) + 1. Subjects who are alive or permanently lost to follow-up at the cut-off date for the analysis will be censored at the last date the subject was known to be alive.
- Secondary Outcome Measures
Name Time Method Progression-free Survival (PFS) Up to approximately 2.5 years PFS will be defined as the time from the date of randomization to the date of first documentation of tumor progression or death from any cause, whichever occurs first.
Objective Response Rate (ORR) Up to approximately 2.5 years The ORR is the percentage of subjects with best overall response of either complete response (CR) or partial response (PR); ORR = CR + PR. Per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, CR was defined as the disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters as confirmed by CT or MRI.
Clinical Benefit Rate (CBR) Up to approximately 2.5 years The CBR is defined as the percentage of subjects with either a CR, PR, or stable disease (SD), relative to the number of subjects in the treatment group. Per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, CR was defined as the disappearance of all target lesions; PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters; and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study, as confirmed by CT or MRI .
Trial Locations
- Locations (220)
Genesis Cancer Center
🇺🇸Hot Springs, Arkansas, United States
Hartford Hospital
🇺🇸Hartford, Connecticut, United States
Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház, Semmelweis Tagkórház, Tüdőgyógyászati Osztály
🇭🇺Miskolc, Hungary
Plano Cancer Institute
🇺🇸Plano, Texas, United States
Istituto Nazionale dei Tumori
🇮🇹Milan, Italy
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Dipartimento di Oncologia, ARNAS Garibaldi
🇮🇹Catania, Italy
Kyungpook National University Medical Center
🇰🇷Daegu, Korea, Republic of
Seoul National University Boramae Medical Center
🇰🇷Seoul, Korea, Republic of
Kosin University Gospel Hospital
🇰🇷Busan, Korea, Republic of
Deenanath Mangeshkar Hospital
🇮🇳Pune, Maharashtra, India
Ballarat Health Services
🇦🇺Ballarat, Victoria, Australia
Komarom-Esztergom Megyei Onkorm. Szent Borbala Korhaza
🇭🇺Tatabanya, Hungary
Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena
🇮🇹Siena, Italy
A.O.U. San Luigi Gonzaga, Orbassano (Torino)
🇮🇹Torino, Italy
Seoul National University Bundang Hospital
🇰🇷Gyeonggi-do, Korea, Republic of
Gachon Universtiy Gil Medical Center
🇰🇷Namdong, Korea, Republic of
Hospital Universitario Lucus Augusti
🇪🇸Lugo, Spain
Centrum Onkologii-Instytut im. Sklodowskiej-Curie
🇵🇱Warszawa, Poland
Oncopremium Team LTD
🇷🇴Baia-Mare, Romania
CHU A Coruña
🇪🇸Coruña, Galicia, Spain
Kyungpook University Chilgok Hospital
🇰🇷Daegu, Korea, Republic of
State Budgetary Healthcare Institution of Arkhangelsk Region Arkhangelsk Clinical Oncology Dispensary
🇷🇺Arkhangelsk, Russian Federation
Chonnam National University Hwasun Hospital
🇰🇷Jeonnam, Korea, Republic of
Hospital Universitario Reina Sofia
🇪🇸Córdoba, Spain
Ospedale Santa Maria della Misericordia, Perugia
🇮🇹Perugia, Italy
State Budgetary Healthcare Institution of Arkhangelsk region "Arkhangelsk Clinical Oncology Dispensary"
🇷🇺Moscow, Russian Federation
Keimyung University Dongsan Medical Centre
🇰🇷Daegu, Korea, Republic of
CHA Bundang Medical Center
🇰🇷Gyeonggi-do, Korea, Republic of
Pusan National University Yangsan Hospital
🇰🇷Gyeongsangnam-do, Korea, Republic of
State Budgetary Healthcare Institution of Sverdlovsk Region, Sverdlovsk Regional Oncology Dispensary
🇷🇺Ekaterinburg, Russian Federation
Department of Medicine, Faculty of Medicine
🇲🇾Kuala Lumpur, Malaysia
Cebu Doctors University Hospital
🇵🇭Cebu City, Philippines
State Budgetary Healthcare Institution of Novosibirsk Region, Novosibirsk Regional Oncology Dispensary
🇷🇺Novosibirsk, Russian Federation
Hospital Universitario Madrid Norte Sanchinarro
🇪🇸Madrid, Spain
State Budgetary Healthcare Institution, Samara Regional Clinical Oncology Dispensary
🇷🇺Samara, Russian Federation
Instituto Catalán de Oncología (ICO) - Josep Trueta
🇪🇸Girona, Spain
Region Budgetary Healthcare Institution, Kursk Regional Clinical Oncology Dispensary of Healthcare Committee of Kursk Region
🇷🇺Kursk, Russian Federation
Emergency County Hospital Satu-Mare, Medical Oncology Clinic
🇷🇴Satu-Mare, Romania
Hospital Universitari Vall d´Hebron
🇪🇸Barcelona, Spain
Complexo Hospitalario Universitario de Ourense (CHUO)
🇪🇸Ourense, Spain
Hospital General Universitário Gregorio Marañón
🇪🇸Madrid, Spain
H. M. Puerta del Sur (H. Móstoles)
🇪🇸Madrid, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
National Cancer Institute of Thailand
🇹🇭Bangkok, Thailand
USC Norris Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
UH Cleveland Medical Center
🇺🇸Cleveland, Ohio, United States
Cancer Treatment Centers of America at Eastern Regional Medical Center
🇺🇸Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center Office of Clinical Research
🇺🇸Philadelphia, Pennsylvania, United States
Princess Alexandra Hospital
🇬🇧Harlow, Essex, United Kingdom
Birla Cancer Centre, SMS Hospital
🇮🇳Jaipur, Rajasthan, India
Department of Medical Oncology, Complex Oncology Center - Burgas EOOD, Burgas
🇧🇬Burgas, Bulgaria
Hetenyi Geza Hospital
🇭🇺Szolnok, Jasz-Nagykun-Szolnok, Hungary
Billings Clinic Cancer Center
🇺🇸Billings, Montana, United States
Koranyi National Institute of TBC and Pulmonology
🇭🇺Budapest, Hungary
Korányi National Institute
🇭🇺Budapest, Hungary
University of Kentucky
🇺🇸Lexington, Kentucky, United States
Medical Oncology Department, Multiprofile Hospital for Active Treatment - Dr. Tota Venkova AD, Gabrovo
🇧🇬Gabrovo, Bulgaria
Clinic of Oncology, UMHAT SofiaMed
🇧🇬Sofia, Bulgaria
St. Vincent Frontier Cancer Center
🇺🇸Billings, Montana, United States
Medical Oncology Department, Specialized Hospital for Active Treatment of Oncology Sveti Mina EOOD - Blagoevgrad
🇧🇬Blagoevgrad, Bulgaria
Clinic of Oncology, UMHAT Dr. Georgi Stranski - Pleven
🇧🇬Pleven, Bulgaria
First Department for Medical Oncology, Multiprofile Hospital for Active Treatement Serdika EOOD, Sofia
🇧🇬Sofia, Bulgaria
Medical Oncology Clinic, Multiprofile Hospital for Active Treatment (MHAT) for Female's Health - Nadezhda OOD, Sofia
🇧🇬Sofia, Bulgaria
Matrai Gyogyintezet
🇭🇺Matrahaza, Hungary
First Department of Medical Oncology, Gastroenterology and Pulmology, Complex Oncology Center - Plovdiv EOOD
🇧🇬Plovdiv, Bulgaria
Multiprofile Clinic Consillium Medulla
🇬🇪Tbilisi, Georgia
Princess Margaret Hospital
🇭🇰Kowloon, Hong Kong
LTD ''Accad. F. Todua Medical Center-Research Institute of Clinical Medicine''
🇬🇪Tbilisi, Georgia
Queen Elizabeth Hospital
🇭🇰Kowloon, Hong Kong
Zala Megyei Szent Rafael Korhaz
🇭🇺Zalaegerszeg, Hungary
Healthcare Global (HCG) Towers
🇮🇳Bangalore, India
Hospital of Lithuanian University of Health Sciences (LSMU) Kauno Klinikos
🇱🇹Kaunas, Lithuania
Hospital Umum Sarawak
🇲🇾Kuching, Malaysia
SC Oncolab LTD
🇷🇴Craiova, Romania
Medisprof LTD
🇷🇴Cluj-Napoca, Romania
Grant Medical Foundation Ruby Hall Clinic
🇮🇳Pune, Maharashtra, India
Sri Venkateshwara Hospitals
🇮🇳Bangalore, Karnataka, India
KLES Dr Prabhakar Kore Hospital & MRC
🇮🇳Nehru Nagar, Karnataka, India
Semmelweis Egyetem AOK Pulmonologiai Klinika
🇭🇺Budapest, Hungary
Veszprém Megyei Tüdőgyógyintézet
🇭🇺Farkasgyepű, Hungary
Tudogyogyintezet Torokbalint
🇭🇺Torokbalint, Hungary
Manila Doctors Hospital
🇵🇭Manila, Philippines
St. Luke's Medical Center - Quezon City
🇵🇭Quezon City, Philippines
Samodzielny Specjalistyczny ZespółZakładów Opieki Zdrowotnej im. dr. Teodora Dunina
🇵🇱Mrozy, Poland
Institute of Oncology Prof. Dr. I.Chiricuta Cluj-Napoca
🇷🇴Cluj-Napoca, Romania
Bhagawan Mahaveer Cancer Hospital
🇮🇳Jaipur, India
Jaslok Hospital & Research Center
🇮🇳Mumbai, Maharashtra, India
Vilnius University Hospital Santaros Klinikos
🇱🇹Vilnius, Lithuania
Hospital Kuala Lumpur
🇲🇾Kuala Lumpur, Malaysia
Davao Doctors Hospital
🇵🇭Davao City, Philippines
Emergency Hospital ,Sf. Ioan cel Nou'
🇷🇴Suceava, Romania
Oncocenter Oncology Clinic LTD
🇷🇴Timisoara, Romania
Szpital Specjalistyczny w Prabutach Sp. z o.o
🇵🇱Prabuty, Pomeranian Voivodeship, Poland
Samodzielny Publiczny Zespół Gruźlicy i Chorób Płuc w Olsztynie
🇵🇱Olsztyn, Warminsko-Mazurskie, Poland
Szpital Chorób Płuc im Św. Józefa w Pilchowicach
🇵🇱Pilchowice, Poland
Wojskowy Instytut Medyczny
🇵🇱Warszawa, Poland
St. Jacob´s Hospital Bardejov - Department of Clinical Oncology
🇸🇰Bardejov, Slovakia
King Chulalongkorn Memorial Hospital
🇹🇭Bangkok, Thailand
Chi Mei Hospital, Liouying
🇨🇳Tainan City, Taiwan
CHU Brest
🇫🇷Brest, France
Service de Pneumologie aiguë et Cancérologie Thoracique Centre hospitalier Lyon-Sud
🇫🇷Pierre Bénite, Rhône-Alpes, France
Centre Paul Strauss
🇫🇷Strasbourg, France
Windsor Regional Hospital Cancer Program
🇨🇦Windsor, Ontario, Canada
State Budgetary Healthcare Institution of Moscow, Moscow City Oncology Hospital #62 of Moscow Healthcare Department
🇷🇺Moscow, Russian Federation
Federal State Budgetary Institution, Scientific Research Institute of Oncology n.a. Petrov
🇷🇺Saint-Petersburg, Russian Federation
State Budgetary Healthcare Institution of Novosibirsk Region, Сity Clinical Hospital #1
🇷🇺Novosibirsk, Russian Federation
Center of Palliative Care-Devita LLC
🇷🇺Saint Petersburg, Russian Federation
Alaska Clinical Research Center
🇺🇸Anchorage, Alaska, United States
Cancer Treatment Centers of America - Western Regional Medical Center
🇺🇸Goodyear, Arizona, United States
Innovative Clinical Research Institute
🇺🇸Whittier, California, United States
Olive View - UCLA
🇺🇸Sylmar, California, United States
VA Palo Alto Health Care System
🇺🇸Palo Alto, California, United States
Alpha Oncology Research LLC
🇺🇸DeBary, Florida, United States
Eastern Connecticut Hematology and Oncology Assoc
🇺🇸Norwich, Connecticut, United States
21st Century Oncology
🇺🇸Louisville, Kentucky, United States
Comprehensive Hematology Oncology
🇺🇸Saint Petersburg, Florida, United States
Winship Cancer Institute, Emory University
🇺🇸Atlanta, Georgia, United States
Northwest Georgia Oncology Centers, P.C.
🇺🇸Marietta, Georgia, United States
Baptist Health Floyd Cancer Center
🇺🇸New Albany, Indiana, United States
Physicians' Clinic of Iowa Hematology and Oncology
🇺🇸Cedar Rapids, Iowa, United States
Kentucky Cancer Clinic
🇺🇸Hazard, Kentucky, United States
Cox Health Medical
🇺🇸Springfield, Missouri, United States
Cancer Treatment Centers of America at Southwestern RMC
🇺🇸Tulsa, Oklahoma, United States
The University of New Mexico Comprehensive Cancer Center
🇺🇸Albuquerque, New Mexico, United States
Kaiser Permanente Northwest Center for Health Research CRSS
🇺🇸Portland, Oregon, United States
Charleston Oncology
🇺🇸Charleston, South Carolina, United States
Prairie Lakes Health Care
🇺🇸Watertown, South Dakota, United States
Spartanburg Medical Center/Gibbs Cancer Center and Research Institute
🇺🇸Spartanburg, South Carolina, United States
Center for Biomedical Research
🇺🇸Knoxville, Tennessee, United States
United Hospital Center
🇺🇸Bridgeport, West Virginia, United States
Camden Clark Medical Center / Regional Cancer Center
🇺🇸Parkersburg, West Virginia, United States
Texas Health Physicians Group
🇺🇸Arlington, Texas, United States
Vista Oncology (Shelton office)
🇺🇸Shelton, Washington, United States
The University of Texas Health Science Center at Tyler, Office of Clinical Studies
🇺🇸Tyler, Texas, United States
Mater Misericordiae Limited and Mater Medical Research Institute Limited
🇦🇺South Brisbane, Queensland, Australia
Mid North Coast Cancer Institute Coff Habour Health Campus
🇦🇺Coffs Harbour, New South Wales, Australia
University of Wisoncsin - Carbone Cancer Ctr
🇺🇸Madison, Wisconsin, United States
Royal Adelaide Hospital
🇦🇺Adelaide, South Australia, Australia
Medical Oncology Department, Multiprofile Hospital for Active Treatment - Dobrich AD, Dobrich
🇧🇬Dobrich, Bulgaria
Medical Oncology Department, Multiprofile Hospital for Active Treatment - Uni Hospital OOD, Panagiurishte
🇧🇬Panagyurishte, Bulgaria
Clinic of Oncology, UMHAT Pulmed
🇧🇬Plovdiv, Bulgaria
Medical Oncology Department, University Multiprofile Hospital for Active Treatment Sv. Ivan Rilski EAD, Sofia
🇧🇬Sofia, Bulgaria
Clinic for Chemotherapy, Specialized Hospital for Active Treatment in Oncology EAD, Sofia
🇧🇬Sofia, Bulgaria
Horizon Health Network - The Moncton Hosoital
🇨🇦Moncton, New Brunswick, Canada
Clinic of Oncology, MHAT Sveta Marina
🇧🇬Varna, Bulgaria
L'Institut Universitaire de Cardiologie et de pneumologie de Quebec
🇨🇦Québec, Quebec, Canada
Cross Cancer Institute - Clinical Trials Unit
🇨🇦Edmonton, Alberta, Canada
McGill University Health Center
🇨🇦Montréal, Quebec, Canada
Princess Margaret Cancer Centre
🇨🇦Toronto, Ontario, Canada
Hopital Nord
🇫🇷Marseille, Alpes-Côte d'Azur, France
Institut de Cancérologie de l'Ouest - Centre Paul Papin
🇫🇷Angers, Pays De La Loire, France
Institut Regional du Cancer de Montpellier
🇫🇷Montpellier, Occitanie, France
Clinique Victor Hugo
🇫🇷Le Mans, Pays De La Loire, France
URCOT : Unité de Recherche Commune en Oncologie Thoracique Service de pneumologie de l'hôpital de la Croix-Rousse
🇫🇷Lyon, Rhône-Alpes, France
Centre François Baclesse
🇫🇷Caen, France
CHI Créteil
🇫🇷Créteil, France
Institut Paoli-Calmettes, Service Dòncologie Médicale
🇫🇷Marseille, France
Institut de Cancérologie de l'Ouest - Centre René Gauducheau
🇫🇷Saint-Herblain, France
Nouvel Hôpital Civil de Strasbourg
🇫🇷Strasbourg, France
LTD High Technology Hospital Medcenter
🇬🇪Batumi, Georgia
High Technology Medical Center, University Clinic
🇬🇪Tbilisi, Georgia
Institute of Clinical Oncology
🇬🇪Tbilisi, Georgia
Queen Mary Hospital
🇭🇰Pokfulam, Hong Kong
Koranyi National Institute of Pulmonology - Horváth
🇭🇺Budapest, Hungary
Istituto Europeo di Oncologia (IEO), Milano
🇮🇹Milan, Italy
Radiation Oncology, Campus Bio-Medico University
🇮🇹Rome, Italy
Chungbuk National University Hospital
🇰🇷Chungcheongbuk-do, Korea, Republic of
Chungnam National University Hospital
🇰🇷Daejeon, Korea, Republic of
Inha University Hospital
🇰🇷Incheon, Korea, Republic of
Ulsan University Hospital
🇰🇷Ulsan, Korea, Republic of
Wonju Severance Christian Hospital
🇰🇷Wonju-Si, Gangwon-do, Korea, Republic of
National Cancer Institute
🇲🇾Putrajaya, Malaysia
St. Luke's Medical Centre
🇵🇭Quezon City, Philippines
Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy
🇵🇱Otwock, Poland
Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandów
🇵🇱Poznań, Poland
SC Oncology Center Sf. Nectarie LTD
🇷🇴Craiova, Romania
Centrum Terapii Wspolczesnej J.M. Jasnorzewska sp. komandytowo-akcyjna
🇵🇱Łódź, Łódź Voivodeship, Poland
Federal State Budgetary Institution, Natiоnal Medical Research Center of Oncology n.a. N.N. Blokhin of Ministry of Healthcare of the Russian Federation
🇷🇺Moscow, Russian Federation
Budgetary Healthcare Institution of Omsk Region, Clinical Oncology Dispensary
🇷🇺Omsk, Russian Federation
State Budgetary Healthcare Institution, Orenburg Regional Clinical Oncology Dispensary
🇷🇺Orenburg, Russian Federation
State Budgetary Healthcare Institution, Leningrad Regional Clinical Hospital
🇷🇺Saint-Petersburg, Russian Federation
Saint-Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary
🇷🇺Saint-Petersburg, Russian Federation
BioEq, LLC
🇷🇺Saint-Petersburg, Russian Federation
State Budgetary Healthcare Institution, Saint-Petersburg Clinical Scientific Practical Center of Specialized Kinds of Medical Care (Oncological)
🇷🇺Saint-Petersburg, Russian Federation
State Budgetary Healthcare Institution of Yaroslavl Region, Regional Oncology Hospital
🇷🇺Yaroslavl, Russian Federation
Hospital Quirón Dexeus
🇪🇸Barcelona, Spain
Faculty Hospital Zilina
🇸🇰Žilina, Slovakia
Hospital Universitario Marqués de Valdecilla
🇪🇸Santander, Cantabria, Spain
Hospital General Universitario de Elche
🇪🇸Elche, Alicante, Spain
Hospital Universitario Puerta de Hierro
🇪🇸Majadahonda, Madrid, Spain
Complejo Hospitalario de Navarra
🇪🇸Pamplona, Navarra, Spain
Hospital General de Alicante
🇪🇸Alicante, Spain
Hospital Regional de Málaga (H. Carlos Haya)
🇪🇸Málaga, Spain
Hospital Virgen de los Lirios Alcoy
🇪🇸Planta, Spain
Corporació Sanitària Parc Taulí
🇪🇸Sabadell, Spain
Hospital Álvaro Cunqueiro
🇪🇸Vigo, Spain
Hospital Universitario y Politécnico de La Fe
🇪🇸Valencia, Spain
Chung Shan Medical University Hospital
🇨🇳Taichung City, Taiwan
Hospital Universitario Virgen de Valme
🇪🇸Sevilla, Spain
E-Da Hospital
🇨🇳Kaohsiung City, Taiwan
Kaohsiung Chang Gung Memorial Hospital
🇨🇳Kaohsiung City, Taiwan
Hospital Lozano Blesa
🇪🇸Zaragoza, Spain
Chang-Gung Memorial Hospital, Linkou
🇨🇳Taoyuan City, Taiwan
Naresuan University Hospital
🇹🇭Phitsanulok, Thailand
Maharaj Nakorn Chiang Mai Hospital
🇹🇭Chiang Mai, Thailand
Srinagarind Hospital
🇹🇭Khon Kaen, Thailand
Songklanagarind Hospital
🇹🇭Songkhla, Thailand
Siriraj Hopsital
🇹🇭Bangkok, Thailand
Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council," Municipal Institution "Multifield Dnipropetrovsk City Hospital #4" of Dnipropetrovsk Regional Council, Department of Chemotherapy
🇺🇦Dnipro, Dnipropetrovsk, Ukraine
Regional Communal Nonprofit Enterprise, Municipal Institution Chernivtsi Regional Clinical Oncology Dispensary, Surgery Department, State Higher Educational Establishment of Ukraine, Bukovinian State Medical University, Department of Onc and Radiology
🇺🇦Chernivtsi, Ukraine
Communal Non-profit Enterprise "Kyiv City Clinical Oncology Center" of Executive body of Kyiv City Council, Kyiv City Clinical Oncology Center by Main Department of Health Protection Kyiv, Hospital of Day Stay for Oncology Patients
🇺🇦Kiev, Ukraine
Municipal Nonprofit Institution "Podilsky Regional Oncology Center" of Vinnytsa City Council, Podilsky Regional Oncology Сenter, Department of Chemotherapy
🇺🇦Vinnitsya, Ukraine
Municipal Nonprofit Institution "Odessa Regional Oncology Dispensary" of Odessa Regional Council, Municipal Institution Odesa Regional Oncology Dispensary, Hospital of Day Stay (Unit of Dispensary-Polyclinic Department)
🇺🇦Odessa, Ukraine
St James' Institute of Oncology
🇬🇧Leeds, United Kingdom
Royal Marsden Hospital
🇬🇧Sutton, United Kingdom
St Bartholomew's Hospital
🇬🇧London, United Kingdom
Royal Free Hospital
🇬🇧London, United Kingdom
Municipal Nonprofit Institution "Cental Municipal Clinical Hospital" of Uzhgorod City Council, Municipal Oncology Centre
🇺🇦Uzhgorod, Zakarpattia, Ukraine
Guy's and St Thomas' NHS Foundation Trust
🇬🇧London, United Kingdom